What is the recommended treatment plan for systemic sclerosis?

Treatment of Systemic Sclerosis

The treatment of systemic sclerosis must be organ-specific and targeted, with mycophenolate mofetil, nintedanib, rituximab, and tocilizumab now representing first-line and second-line options for the critical fibrotic manifestations of skin and lung disease that drive mortality. 1

Organ-Specific Treatment Approach

The 2025 EULAR recommendations fundamentally changed SSc management by introducing the first synthetic and biological targeted therapies for fibrotic manifestations, covering 8 clinical domains with 22 specific recommendations 1. Treatment must be tailored to the specific organ involvement, as SSc remains the rheumatic disease with the highest morbidity and mortality despite recent survival improvements 1.

Interstitial Lung Disease (ILD) - The Critical Domain

For SSc-ILD, mycophenolate mofetil is the strongest first-line recommendation 2. The American Thoracic Society 2024 guideline provides the highest level of evidence, making a strong recommendation specifically for mycophenolate based on its efficacy and safety profile 2.

Treatment algorithm for SSc-ILD:

• Early inflammatory ILD: Consider mycophenolate mofetil and/or rituximab, with cyclophosphamide as an alternative 1
• Progressive fibrosing ILD: Nintedanib should be considered alone or in combination with mycophenolate 1
• Alternative options: Tocilizumab should be considered, particularly in early inflammatory disease (FDA-approved for SSc-ILD) 1
• Second-line options: Rituximab for patients not responding to initial therapy 1

The SENSCIS trial demonstrated nintedanib reduced FVC decline by 41% annually (difference of 41.0 mL/year, p=0.04), with effects maintained whether or not patients were on background mycophenolate 1. The INBUILD trial further validated nintedanib in progressive fibrosing ILD, showing a difference of 102.7 mL/year in FVC decline 1.

Skin Fibrosis

For significant skin involvement (modified Rodnan skin score ≥15):

• First-line: Mycophenolate mofetil 1, 3
• Second-line: Methotrexate 3
• Severe progressive disease (MRSS ≥32): Consider rituximab or tocilizumab 1, 3
• Very severe with poor prognosis: High-intensity immunosuppression with autologous hematopoietic stem cell transplantation may be considered in selected patients with early severe diffuse cutaneous SSc, absent advanced cardiorespiratory involvement 1

The SCOT study at 54 months demonstrated superior outcomes for autologous HSCT over cyclophosphamide for severe disease 1.

Pulmonary Arterial Hypertension (PAH)

First-line combination therapy is now standard for newly diagnosed PAH 1:

• Mild PAH: Phosphodiesterase-5 inhibitors, then add endothelin receptor antagonists 3
• Severe PAH: Prostanoids as first-line treatment 3
• Progressive disease: Triple combination therapy including prostanoids 3

Raynaud's Phenomenon

Treatment escalation based on severity:

• Mild RP: Calcium-channel blockers (first-line), then add PDE5 inhibitors, then add ARBs or switch CCB 3
• Severe RP: CCBs plus PDE5 inhibitors or prostanoids 3

Digital Ulcers

Active treatment algorithm:

• First-line: Calcium-channel blockers and PDE5 inhibitors 3
• Refractory: Intravenous prostanoids 3

Scleroderma Renal Crisis

Immediate aggressive treatment is essential:

• First-line: ACE inhibitors 3
• Second-line: Add calcium-channel blockers 3
• Third-line: Add angiotensin receptor blockers 3

81% expert agreement supports this algorithm, emphasizing the critical importance of rapid ACE inhibitor initiation 3.

Gastrointestinal Manifestations

Treatment addresses specific GI complications including esophageal dysmotility, gastroparesis, and intestinal pseudo-obstruction, though specific pharmacologic recommendations require individualization based on the manifestation 1.

Inflammatory Arthritis

When musculoskeletal involvement is prominent:

• First-line: Methotrexate 3
• Second-line: Low-dose glucocorticoids 3
• Third-line: Hydroxychloroquine 3
• Fourth-line: Rituximab or tocilizumab 3

Critical Clinical Pitfalls

Avoid delayed treatment initiation: SSc-ILD and skin fibrosis progress rapidly in early disease. The window for maximum treatment benefit is narrow, particularly in the first 3-5 years 1.

Do not use high-dose corticosteroids: These increase the risk of scleroderma renal crisis and should be avoided except at low doses for specific indications like inflammatory arthritis 3.

Monitor for progressive fibrosing ILD: Even patients on immunosuppression may develop PF-ILD requiring addition of nintedanib 1. Reassess at 6 months with pulmonary function testing.

Combination therapy is now standard: The paradigm has shifted from monotherapy to rational combinations, particularly nintedanib plus mycophenolate for ILD and combination therapy for PAH 1.

Key Evidence Considerations

The 2025 EULAR recommendations represent the most comprehensive and recent guideline, incorporating evidence through 2023 1. These align substantially with the 2024 American Thoracic Society recommendations for SSc-ILD, which provide the strongest evidence grade specifically for mycophenolate 2. The convergence of multiple international guidelines (EULAR, ATS, ACR-ACCP, ERS-EULAR) on similar treatment approaches strengthens confidence in these recommendations 4.

The major advancement is the inclusion of targeted therapies (rituximab, tocilizumab, nintedanib) that directly address fibrotic mechanisms, moving beyond traditional immunosuppression alone 1. This reflects improved understanding of SSc pathophysiology and provides options when first-line therapies prove insufficient.